Latest News and Press Releases

ROCKVILLE, Md., May 18, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today that it is launching a two-year, quarterly professional education curriculum for interdisciplinary...

ROCKVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) released its sixth annual State of the States: Living Donor Protection Report Card. While AKF has helped lead...

ROCKVILLE, Md., April 23, 2026 (GLOBE NEWSWIRE) -- Today, the nation’s leading kidney health organizations will convene on Capitol Hill for an educational briefing, “Kidney Diseases: the Hidden...

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership...

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) is kicking off its seventh annual Kidney Action Week®, the only free, virtual conference in the country that...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...

Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.

Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.

Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.